

**South East London Area Prescribing Committee  
Formulary recommendation**

<b>Reference</b>	<b>030</b>
<b>Intervention:</b>	<b>Sodium cromoglycate 4% cutaneous emulsion (Altoderm™) for the treatment of mastocytosis in children</b> Sodium cromoglycate is a mast cell stabiliser that works by inhibiting the release of inflammatory mediators (such as histamine) from mast cells.
<b>Date of Decision</b>	<b>April 2015</b>
<b>Date of Issue:</b>	<b>May 2015</b>
<b>Recommendation:</b>	<b>Grey – not recommended for prescribing in South East London</b>
<b>Further Information</b>	<ul style="list-style-type: none"> <li>• The evidence to support the use of topical sodium cromoglycate in mastocytosis is weak.</li> <li>• Existing data are limited to one case report in a single patient.</li> </ul>
<b>Shared Care/Transfer of care document required:</b>	N/A
<b>Cost Impact for agreed patient group</b>	N/A
<b>Usage Monitoring &amp; Impact Assessment</b>	Trusts – monitor non-formulary requests
	CCGs – monitor impact data
<b>Evidence reviewed</b>	N/A

**NOTES:**

- a) Area Prescribing Committee recommendations and minutes are available publicly on member CCG websites.
- b) This Area Prescribing Committee recommendation has been made on the cost effectiveness, patient outcome and safety data available at the time. The recommendation will be subject to review if a submission is received or new NICE guidelines or technology appraisals are issued.
- c) **Not to be used for commercial or marketing purposes. Strictly for use within the NHS**